SquamousCellCarcinomaofSkin near Hackensack, NJ

Biography: Dr. Chris Hackett received his BS in Biological Sciences from Stanford University in 2000. After doing biomedical research in industry and academia, he then pursued graduate studies in cancer genomics at the University of California, San Francisco, where he earned his PhD in 2010. Seeking to become a physician-scientist, he then earned his medical degree (MD) from the University of Minnesota in 2014. He then completed his Internal Medicine Residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center (MSK), where he focused on solid tumor oncology in the clinic and carried out laboratory research to design T cell therapies for cancer. Following fellowship, Dr. Hackett was an attending on the Cellular Therapeutics Service at MSK, where he focused on treating patients with CAR T cells, Tumor Infiltrating Lymphocytes (TIL) and other cell therapies. In 2023, he joined the Bone Marrow Transplant Service at Weill Cornell Medicine and NewYork-Presbyterian Hospital, where he continues to both treat patients with cellular therapies and conduct research to develop new cell therapies for solid tumors.

Biography: Ghaith Abu-Zeinah, MD, is an Assistant Professor in Medicine at Weill Cornell Medical College and an Assistant Attending Physician at the NewYork-Presbyterian Hospital. Dr. Abu-Zeinah earned his M.D. with academic distinction from the Weill Cornell Medical College in Qatar in 2013. He completed his residency training in Internal Medicine (2016) and fellowship training in Hematology/Oncology (2019) at the NewYork-Presbyterian Hospital/Weill Cornell Medicine in New York City.Dr. Abu-Zeinah is a Hematologist and Oncologist with a specialty practice in Myeloproliferative Neoplasms (MPN). His laboratory and clinical research is focused on identifying and developing therapies that target the malignant stem cells in patients with MPN. He received several awards for his work and presented at national conferences including the International Congress on Myeloproliferative Neoplasms and the American Society of Hematology. He has joined the Richard T Silver MPN Center as a physician-scientist both treating patients and conducting research.

Biography: Alexandra Gomez Arteaga, M.D., is Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York-Presbyterian Hospital. She specializes in the care of patients with hematological malignancies and other disorders who need a blood or bone marrow stem cell transplant or cellular therapies.Dr. Gomez received her M.D. (Valedictorian) from Los Andes University in Bogota, Colombia, in 2011. She completed her Internal Medicine residency at the University of Miami/Jackson Memorial Hospital and her Hematology/Oncology fellowship at Weill Cornell Medicine/New York-Presbyterian Hospital, where she also served as Chief Fellow. Subsequently, she completed an advanced fellowship in Bone Marrow Transplantation at Memorial Sloan Kettering Cancer Center. Upon completion of her training, Dr. Gomez was recruited back to Weill Cornell Medicine/New York-Presbyterian Hospital to join the faculty of the Bone Marrow Transplant Program.Dr. Gomez's main research focus is relapse prevention strategies and management of disease relapse after a stem cell transplant. She has published in leading internationally circulated peer-reviewed journals, among them Cancer, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, the American Journal of Hematology, Leukemia & Lymphoma. She is a member of the American Society for Transplantation and Cellular Therapy (ASTCT), the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the Society for Immunotherapy of Cancer (SITC).

Biography: Samuel Yamshon, M.D. is an Assistant Professor of Medicine at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Yamshon cares for patients with blood cancers with a specific focus on lymphoma and improving outcomes for patients using innovative treatments like cellular immunotherapies including CAR T-cell therapy.Dr. Yamshon received his B.A. from Columbia University and completed his medical training at the University of California, Davis. He returned to New York to train in Internal Medicine at Weill Cornell Medicine, where he also completed his fellowship in Hematology and Oncology. At Weill Cornell Medicine, he specializes in treating patients with lymphoma using cellular therapies including bone marrow transplantation and CAR T cell therapy, and is involved in clinical research dedicated to improving outcomes for patients with lymphoma. He has been involved in lymphoma research for over a decade, co-authoring numerous publications and several presentations at national meetings. Dr. Yamshon is also an Editorial Fellow for the journal Leukemia & Lymphoma. He has received multiple research grants including the American Society of Clinical Oncology (ASCO) Young Investigator Award and the Lymphoma Research Foundation (LRF) Scientific Research Mentoring Program.